Mangoceuticals clarifies GLP-1 weight-management program launch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil rises as Trump repeats Iran attack threat
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
November 13, 2025 7:37 PM ESTDallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (Mangoceuticals or the Company) is issuing the following clarification regarding its press release issued earlier this morning titled Mangoceuticals Partners with Eli Lilly and Novo Nordisk.
The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 medications, including, when medically appropriate, Zepbound® from Eli Lilly and Wegovy® from Novo Nordisk. These programs allow Mangoceuticals patients to access, for the first time,... More
